ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 115

Composite Ultrasound Score in Spondyloarthropathies

Maria L. Acosta Felquer1, Cristian Quiroz2, Santiago Ruta3, Javier Rosa4, Marina Scolnik2, Leandro Ferreyra Garrott3, Ricardo Garcia-Monaco5 and Enrique R. Soriano6, 1Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, 6Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, spondylarthropathy and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose: A comprehensive ultrasound (US) scoring system which includes enthesitis tenosynovitis and synovitis for use in patients with spondyloarthropathies (SpA) is not yet available. The objective of the study was to develop an US composite scoring system, including both enthesitis tenosynovitis and synovitis, suitable for the evaluation of patients with SpA.

Methods: Consecutive patients with SpA according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial, and/or peripheral spondyloarthritis and Rheumatoid arthritis (RA) patients fulfilling ACR/EULAR criteria (control group) in whom an US was performed were included. US examination was done by an experienced rheumatologist using both grey scale US and power Doppler (PD). The following articular areas were assessed:  2-3 MCP joints, 2-3 proximal PIP joints, wrist, knee and second and fifth MTP joints. Knee and ankle entheses were examined. Both second and third flexor and fourth and sixth extensor tendons of the hands were examined for tenosynovitis. Synovitis, tenosynovitis and enthesitis were defined according to OMERACT preliminary definitions.  Both GS and PD synovitis were graded on a semiquantitative scale from 0 to 3. For each one of the structures examined (enthesis, tendons and synovial) an initial US score was obtained by multiplying the semiquantitative scale by the number of sites involved. Using that score patients were classified into a new US structure specific (enthesis, tendons and synovial) activity score ranging from 0 (no activity) to 3 (severe activity) for that structure. Finally adding the US structure specific activity scores a composite US activity score was constructed ranging from 0 (no activity) to 3 (severe activity).

Results: 33 patients with SpA (70% males, mean (SD) age: 51 (14.6) and 35 with RA (97% females, mean (SD) age: 55.7 (16) were included.

Table.Comparison of different variables related to disease activity in the different US composite activity score classification groups in patients with SpA and RA.

 

SpA

US  composite  activity score classification

N patients (%)

Mean DAS28 (SD)

 Mean ESR (SD)

 Mean HAQ (SD)

Mean VAS Physician (SD)

Mean CPDAI (SD)

0 (none involvement)

1 (3)

2.3 (0)

18 (0)

0.25 (0)

20 (0)

0 (0)

1 (mild)

26 (79)

3.99 (0.9)

21 (15.8)

0.63 (0.54)

46.5 (20)

3.3(1.9)

2 (moderate)

6 (18)

5.15 (1.3)

36 (31)

1.33 (0.8)

46.7 (27)

4.2 (3.9)

3 (severe)

0 (0)

–

 

–

–

–

P value (1-mild vs 2-moderate) Mann Whitney

 

0.1366

0.2107

0.0477

0.9197

0.9363

 

RA

US  global severity classification

N patients (%)

Mean DAS28 (SD)

 Mean ESR (SD)

 Mean HAQ (SD)

Mean VAS Physician (SD)

Mean CDAI (SD)

0 (none involvement)

0 (0)

–

–

–

–

–

1 (mild)

24 (69)

4.6 (1)

21 (15.8)

0.94 (0.83)

40.6 (22)

17.9 (8.6)

2 (moderate)

11 (3)

5.7 (0.7)

36 (31)

1.22 (0.9)

63 (20)

29.2 (9.2)

3 (severe)

0 (0)

–

–

–

–

–

P value (1-mild vs 2-moderate) Mann Whitney

 

0.0067

0.2551

0.386

0.008

0.0051

Most patients were classified as with mild disease activity by the US composite activity classification score in both diseases SpA and RA. In both diseases patients with higher US cmposite score had higher indices of disease activity although the differences were not always significant.

Conclusion:  An US composite activity classification score taking into account synovial, enthesis and tendons involvement proved to correctly discriminate patients with SpA and RA in different activity status according to classical activity indices.


Disclosure:

M. L. Acosta Felquer,
None;

C. Quiroz,
None;

S. Ruta,
None;

J. Rosa,
None;

M. Scolnik,
None;

L. Ferreyra Garrott,
None;

R. Garcia-Monaco,
None;

E. R. Soriano,

Abbott Immunology Pharmaceuticals,

2,

Janssen Pharmaceutica Product, L.P.,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/composite-ultrasound-score-in-spondyloarthropathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology